François-Clément Bidard
Led PADA-1, the first trial to switch endocrine therapy on a rising ESR1 mutation in blood.
François-Clément Bidard leads medical oncology at Institut Curie and pioneered ctDNA-guided endocrine switching in HR-positive breast cancer with the PADA-1 trial; he also led the EMERALD trial of elacestrant.
Pages like this
not linked directly; found by shared links- TermSelective oestrogen receptor degrader (SERD)
Shares EMERALD, Fulvestrant, Elacestrant, Estrogen receptor (ERα).
- TermOral SERD
Shares Fulvestrant, Elacestrant, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- TrialVERITAC-2
Shares Fulvestrant, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- TermESR1 mutation
Shares EMERALD, Elacestrant, Estrogen receptor (ERα), Liquid biopsy (ctDNA).
- TrialpostMONARCH
Shares Fulvestrant, HR-positive / HER2-negative breast cancer.
- CompanyMenarini / Stemline
Shares Elacestrant, HR-positive / HER2-negative breast cancer.
- TrialSOLAR-1
Shares Fulvestrant, HR-positive / HER2-negative breast cancer.
- TrialINAVO120
Shares Fulvestrant, HR-positive / HER2-negative breast cancer.